Celgene Pulls Back From First-Line CLL As Revlimid ORIGIN Trial Terminates
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Imbalance of deaths for Revlimid in the ORIGIN treatment-naïve CLL study could be due to the advanced age of participants or their many comorbidities. Future of drug as monotherapy in treatment-naïve patients is now unlikely, but studies in later lines of treatment go on.
You may also be interested in...
Celgene Goes Big And Early: Aims For Two New Blockbusters And A Robust, Transformative Pipeline
The biotech has a three-pronged strategy to double revenues by 2017: continue to expand core multiple myeloma product Revlimid, bring new blockbusters online, and develop its early stage pipeline through deals.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.